Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab

Affiliations

• ¹ Department of Neurology, Washington University, St. Louis, MO, USA. [email protected].
• ² University of Miami Miller School of Medicine, Miami, FL, USA.
• ³ University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia.
• ⁴ Moscow State Public Healthcare InsCity Clinical Hospital 24, Moscow, Russia.
• ⁵ Infectious Diseases Division, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
• ⁶ UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
• ⁷ First Saint Petersburg State Medical University, St. Petersburg, Russia.
• ⁸ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
• ⁹ Novartis Pharma B.V., Amsterdam, The Netherlands.
• ¹⁰ Novartis Healthcare Private Limited, Hyderabad, India.
• ¹¹ Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
• ¹² School of Public Health at Oregon Health and Science University, Portland, OR, USA.